Document is current
Any future updates will be listed below
-
Authors
Hofeld, Benjamin C.
Puppala, Venkata K.
Tyagi, Sudhi
Ahn, Kwang Woo
Anger, Amberly
Jia, Shuang
Salzman, Nita H.
Hessner, Martin J.
Widlansky, Michael E.
-
Funding
Funding for this research was provided by:
National Institutes of Health,United States (R38HL143561)
National Institutes of Health (T32HL007792, DK088831, DK121528, HL125409)
- License Information
-
More Information
Article History
Received: 14 October 2020
Accepted: 25 January 2021
First Online: 17 February 2021
Competing interests
: Dr. Widlansky is supported in part by HL144098 that focuses on the impact of <i>Lp299v</i> supplementation. Probi (Lund, Sweden), the manufacturer of <i>Lp299v</i>, supports HL144098 through the donation of product. Probi did not donate any product for studies reported in this manuscript. Dr. Hessner is also supported in part by DK125014 which studies the effect of <i>Lp299v</i> on innate inflammation in type 1 diabetes.
